425 related articles for article (PubMed ID: 8957644)
1. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Wolkenstein P; Chosidow O; Fléchet ML; Robbiola O; Paul M; Dumé L; Revuz J; Roujeau JC
Contact Dermatitis; 1996 Oct; 35(4):234-6. PubMed ID: 8957644
[TBL] [Abstract][Full Text] [Related]
2. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Ding WY; Lee CK; Choon SE
Int J Dermatol; 2010 Jul; 49(7):834-41. PubMed ID: 20618508
[TBL] [Abstract][Full Text] [Related]
4. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.
Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM
Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511
[TBL] [Abstract][Full Text] [Related]
5. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Harr T; French LE
Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
[TBL] [Abstract][Full Text] [Related]
6. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM
Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
Teraki Y; Shibuya M; Izaki S
Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
[TBL] [Abstract][Full Text] [Related]
8. Adverse cutaneous drug eruptions: current understanding.
Hoetzenecker W; Nägeli M; Mehra ET; Jensen AN; Saulite I; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
Semin Immunopathol; 2016 Jan; 38(1):75-86. PubMed ID: 26553194
[TBL] [Abstract][Full Text] [Related]
9. Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature.
van Hattem S; Beerthuizen GI; Kardaun SH
Br J Dermatol; 2014 Dec; 171(6):1539-45. PubMed ID: 24888401
[TBL] [Abstract][Full Text] [Related]
10. The use of patch tests in the diagnosis of delayed hypersensitivity drug eruptions.
Hassoun-Kheir N; Bergman R; Weltfriend S
Int J Dermatol; 2016 Nov; 55(11):1219-1224. PubMed ID: 27368159
[TBL] [Abstract][Full Text] [Related]
11. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome.
Sharma VK; Sethuraman G; Minz A
Indian J Dermatol Venereol Leprol; 2008; 74(3):238-40. PubMed ID: 18583791
[TBL] [Abstract][Full Text] [Related]
12. Toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Orphanet J Rare Dis; 2010 Dec; 5():39. PubMed ID: 21162721
[TBL] [Abstract][Full Text] [Related]
13. Severe acute generalized exanthematous pustulosis with blistering mimicking toxic epidermal necrolysis, associated with a primary mumps infection.
Azib S; Florin V; Fourrier F; Delaporte E; Staumont-Sallé D
Clin Exp Dermatol; 2014 Aug; 39(6):723-5. PubMed ID: 24986490
[TBL] [Abstract][Full Text] [Related]
14. Drug patch testing in Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review.
Novack DE; Braskett M; Worswick SD; Adler BL
Ann Allergy Asthma Immunol; 2023 May; 130(5):628-636. PubMed ID: 36649833
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study.
Barvaliya M; Sanmukhani J; Patel T; Paliwal N; Shah H; Tripathi C
J Postgrad Med; 2011; 57(2):115-9. PubMed ID: 21654132
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous adverse drug eruption: the role of drug patch testing.
Thaiwat S; Rojanapanthu P
Int J Dermatol; 2023 Jan; 62(1):108-114. PubMed ID: 36300773
[TBL] [Abstract][Full Text] [Related]
17. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
Mustafa SS; Ostrov D; Yerly D
Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
[TBL] [Abstract][Full Text] [Related]
18. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?
Bouvresse S; Valeyrie-Allanore L; Ortonne N; Konstantinou MP; Kardaun SH; Bagot M; Wolkenstein P; Roujeau JC
Orphanet J Rare Dis; 2012 Sep; 7():72. PubMed ID: 23009177
[TBL] [Abstract][Full Text] [Related]
19. Adverse drug reactions and organ damage: The skin.
Marzano AV; Borghi A; Cugno M
Eur J Intern Med; 2016 Mar; 28():17-24. PubMed ID: 26674736
[TBL] [Abstract][Full Text] [Related]
20. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.
Rzany B; Correia O; Kelly JP; Naldi L; Auquier A; Stern R
Lancet; 1999 Jun; 353(9171):2190-4. PubMed ID: 10392983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
